Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug:507:164-166.
doi: 10.1016/j.cca.2020.04.026. Epub 2020 Apr 25.

IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study

Andrea Padoan  1 , Laura Sciacovelli  2 , Daniela Basso  1 , Davide Negrini  3 , Silvia Zuin  3 , Chiara Cosma  2 , Diego Faggian  2 , Paolo Matricardi  4 , Mario Plebani  5
Affiliations

IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study

Andrea Padoan et al. Clin Chim Acta. 2020 Aug.

Abstract

Validation studies of serological antibody tests must be properly designed for clinical, epidemiological and Public Health objectives such as confirmation of suspected COVID-19 cases, certification of seroconversion after infection, and epidemiological surveillance. We evaluated the kinetics of IgM, IgA and IgG SARS-CoV-2 antibodies in COVID-19 patients with confirmed (rRT-PCR) infection. We found that the IgA response appears and grows early, peaks at week 3, and it is stronger and more persistent than the IgM response. Further longitudinal investigations of virus-specific antibodies functions and of their protective efficacy over time are needed.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kinetics of IgA (ELISA) and IgM (CLIA) of patients monitored from the onset of symptoms (fever).
Fig. 2
Fig. 2
Spaghetti plot of patients with more than 3 serial antibody determinations after the onset of symptoms (fever): A) IgA (n = 17 patients); B) IgM (n = 18 patients).
Supplementary figure 1
Supplementary figure 1
See this image and copyright information in PMC

References

    1. Mizumoto K., Kagaya K., Zarebski A., Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10) doi: 10.2807/1560-7917. - DOI - PMC - PubMed
    1. T.F. Amana, T.H.O. Nguyen, V. Chromikova, S. Strohmeier, D. Stadblauer, Javier A et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv http://doi.org/10.1101/2020.03.17.20037713. - PMC - PubMed
    1. Okba Nisreen M.A., Müller Marcel A., Li Wentao, Wang Chunyan, GeurtsvanKessel Corine H., Corman Victor M., Lamers Mart M., Sikkema Reina S., de Bruin Erwin, Chandler Felicity D., Yazdanpanah Yazdan, Le Hingrat Quentin, Descamps Diane, Houhou-Fidouh Nadhira, Reusken Chantal B.E.M., Bosch Berend-Jan, Drosten Christian, Koopmans Marion P.G., Haagmans Bart L. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease 2019 Patients. Emerg. Infect. Dis. 2020;26(7) doi: 10.3201/eid2607.200841. - DOI - PMC - PubMed
    1. A. Padoan, C. Cosma, L. Sciacovelli, D. Faggian, M. Plebani, Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin. Chem. Lab. Med. 2020 Apr 16. pii:/j/cclm.ahead-of-print/cclm-2020-0443/cclm-2020-0443.xml. http://doi.org/10.1515/cclm-2020-0443. [Epub ahead of print]. - PubMed
    1. R. Lassauniere, A. Frische, Z.B. Harboe, A.C.Y. Nielsen, A. Fomsgaard, K.A. Krogfelt et al. Evaluation of nine commercial SARS-CoV-2 immunoassays, medrxv http://doi.org/10.1101/2020.04.09.20056325.

MeSH terms